<DOC>
	<DOCNO>NCT01737814</DOCNO>
	<brief_summary>The purpose study evaluate whether MST-188 reduce duration vaso-occlusive crisis ( VOC ) subject sickle cell disease . The study also evaluate whether MST-188 reduce frequency rehospitalization subject due recurrence VOC . Additionally , study compare development acute chest syndrome VOC subject receive MST-188 receive MST-188 .</brief_summary>
	<brief_title>Evaluation Purified Poloxamer 188 Vaso-Occlusive Crisis Sickle Cell Disease ( EPIC )</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Age 4 65 year Subject confirm diagnosis HbSS , HbSC , HbSβ+thal , HbSβ0thal Subject experience acute pain typical vasoocclusive crisis require treatment parenteral analgesia Subject require hospitalization Subject acute chest syndrome Subject 's laboratory result indicate inadequate organ function Subject pregnant nursing infant Subject painful crisis require hospitalization within precede 14 day experience &gt; 5 hospitalization VOC prior 6 month Subject transfuse within past 14 day Subject hospitalize condition VOC Subject complication relate SCD</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>vaso-occlusive crisis</keyword>
</DOC>